Third generation oral contraceptives-- the controversy

Authors:
  • DCD Carnall
    D Carnall
  • HKH Karcher
    H Karcher
  • LLL G Lie
    L G Lie
  • TST Sheldon
    T Sheldon
  • DSD Spurgeon
    D Spurgeon
  • DJD Josefson
    D Josefson
  • CZC Zinn
    C Zinn

Abstract
In Britain the Committee on Safety of Medicines chose not to withdraw the licences of the brands associated with the increased risk, estimated at 30 cases of venous thromboembolism for every 100000 users a year, compared with 15 cases for every 100000 users of other brands. But the committee did write to Britain's 190000 doctors and pharmacists, advising them of its decision. The Department of Health convened a press conference, and the story hit the headlines. Large numbers of women contacted their general practitioners for further advice. Interest was fuelled by a flying visit from the author of one of the unpublished studies on which the committee's decision was based, Professor Spitzer, complaining that the committee had misused his data.